Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00160693. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.
Study identification
- NCT ID
- NCT00160693
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 402 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2003 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Feb 2011 (Actual)
- Last update posted
- Aug 1, 2018
2003 – 2011
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Paradise Valley | Arizona | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Coeur d'Alene | Idaho | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Fall River | Massachusetts | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Erie | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Duncanville | Texas | — | — |
| Not listed | Lubbock | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | San Diego | Texas | — | — |
| Not listed | Everett | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00160693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 1, 2018 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.